Evaluation of the Safety and Efficacy of the NuEra Tight VRF for the Treatment of Vaginal and Vulvar Tissue Laxity
NCT ID: NCT04511260
Last Updated: 2020-12-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
20 participants
INTERVENTIONAL
2020-10-16
2021-06-20
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This is a single center, prospective, open label, single arm study. Following screening visit, eligible subjects will be enrolled into the study. Each subject will receive 3 treatments, 4 weeks apart and 2 Follow Up (FU) visits, at 1, and 3 months following the last treatment.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
VRF Treatment
A treatment of the vaginal canal using the NuEra Tight VRF small area handpiece. A treatment of the introitus and vestibule using the NuEra Tight VRF small area hand piece (optional).
Following screening visit, eligible subjects will be enrolled into the study. Each subject will receive 3 treatments, 4 weeks apart and 2 Follow Up (FU) visits, at 1, and 3 months following the last treatment.
NuEra Tight VRF Handpiece
The VRF is a Model that belongs to the NuEra Tight RF Family, specific for the treatment of small areas.
The NuEra is FDA cleared (K151296) for a wide range of indications including but not limited to, selected medical conditions such as temporary relief of pain, muscle spasms, and increase in local circulation. The NuEra Tight VRF with the small area handpiece is CE marked in Europe and currently under review by the FDA. The system and its accessories, are intended to be use for a wide range of indications including, but not limited to:
· Provide heating for the purpose of elevating tissue temperature for selected medical conditions such as temporary relief of pain, muscle spasms, and increase in local circulation of soft tissue.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
NuEra Tight VRF Handpiece
The VRF is a Model that belongs to the NuEra Tight RF Family, specific for the treatment of small areas.
The NuEra is FDA cleared (K151296) for a wide range of indications including but not limited to, selected medical conditions such as temporary relief of pain, muscle spasms, and increase in local circulation. The NuEra Tight VRF with the small area handpiece is CE marked in Europe and currently under review by the FDA. The system and its accessories, are intended to be use for a wide range of indications including, but not limited to:
· Provide heating for the purpose of elevating tissue temperature for selected medical conditions such as temporary relief of pain, muscle spasms, and increase in local circulation of soft tissue.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Last vaginal delivery is at least 12 months prior to enrollment
* Self-reported vaginal laxity defined as "very loose," "moderately loose," or "slightly loose" on the Vaginal Laxity Questionnaire (VLQ)
* Sexual activity≥ once per month, with a same partner
* Willing to use contraception for the duration of the study
* Negative urine analysis
* Negative pregnancy test
* Patient is not pregnant nor planning to become pregnant throughout the duration of the study
* Willing to improve vaginal lips / genitals appearance (optional)
* Normal gynecological exam from the recent year
* If taking probiotics and/or any other supplement or suppository as part of daily regimen, willing to maintain same regimen throughout the entire duration of the study
* Able and willing to comply with the treatment/follow-up schedule and requirements ·
* Willing to sign an informed consent
Exclusion Criteria
* Pelvic organ prolapse (POP) \>II according to the pelvic organ prolapse quantification system
* Pregnant or lactating
* Women in post-menopausal stage for more than five years.
* Active genital infection or sexually transmitted diseases
* Subject presenting abnormal Pap smear result from the last five years with any of the following findings according to the Bethesda System (2001) classification: A.. Atypical Squamous Cells-cannot exclude high grade squamous intraepithelial lesion B. Atypical Glandular Cells (Endocervical, Endometrial not otherwise specified) C. High Grade squamous intraepithelial lesion (HSIL)D. Carcinoma
* Patients with implantable devices, such as but not limited to pacemakers, implanted defibrillators, and Cochlear ear implant
* Serious systemic disease or any chronic condition that could interfere with study compliance
* Has metal implant(s) within the treated area, such as surgical clips, plates and screws, intrauterine device (IUD) or artificial joints
* History of diseases stimulated by heat, such as recurrent herpes zoster in the treatment area, unless treatment is conducted following a prophylactic regimen.
* History of vaginal tissue disease in the treatment area
* Taken part in a clinical trial involving an investigational drug or device within 30 days prior to screening and through the study duration
* Presence of Vulvar lesions or any other reason that, in the opinion of the investigator, prevents the subject from participating in the study or compromise the subject safety
* Nerve insensitivity to heat anywhere in the treatment area, since ongoing feedback by a patient during a procedure is required
* Previous treatment with a vaginal energy based device, including laser treatment.
* Any other reason that, in the opinion of the investigator, prevents the subject from participating in the study or compromise the subject safety
35 Years
60 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Lumenis Be Ltd.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
NYDerm
New York, New York, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
NYDerm
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
LUM-ABU- NuEra VRF 20-01
Identifier Type: -
Identifier Source: org_study_id